Study with Chronic Fatigue Syndrome patients supplemented with ReConnect

At Vitae we have carried out a clinical study with 207 patients with Chronic Fatigue Syndrome, with diagnosis and follow-up, carried out at the Vall d’Hebron University Hospital in Barcelona. This study has been published in the prestigious scientific journal Nutrients with an Impact of 5,717. The research follows the course of previous studies published in the scientific journals Antioxidants, Clinical Nutrition and Revista Clínica Española.

Here is a brief summary of the study.

Effect of Dietary Coenzyme Q10 Plus NADH Supplementation on Fatigue Perception and Health-Related Quality of Life in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial

 Researchers: Castro-Marrero, J .; Second, M.J .; Lacasa, M .; Martinez-Martinez, A .; Sentañes, R.S .; Alegre-Martin, J.

Research centers: Rheumatology Service Hospital Univ. Vall d’Hebron Clinical Research Department Vitae Health Innovation. Institute of Oncology Hospital Univ. Vall d’Hebron


  • Primary: Efficacy of ReConnect in chronic fatigue syndrome (CFS)
  • Changes in fatigue, both mental and physical, after 8 weeks of supplementation with ReConnect vs placebo (measured by FIS-40 scale)
  • Secondary: Assessment of the quality of sleep and quality of life
  • Changes in Sleep Quality (Pittsburgh Index, PSQI)
  • Changes in Quality of Life (includes mental and physical functional status, SF-36)

Materials and methods:

  • Prospective, randomized, double-blind and controlled study vs placebo.
  • Participants n = 207; adult women (over 18 years old) with a confirmed diagnosis of Chronic Fatigue Syndrome.
  • 8-week treatment with tablets containing coenzyme Q10 (200mg) + NADH (20mg) daily.
  • Questionnaires throughout the study to measure efficacy in chronic fatigue, sleep quality and quality of life (FIS-40 / PSQI / F-36 respectively)


  • The CoQ10 + NADH combination improves cognitive fatigue at weeks 4 and 8 of treatment, with statistically significant differences compared to baseline fatigue (p<0.01).
  • The CoQ10 + NADH combination improves chronic fatigue globally, reducing the global FIS-40 score significantly after 4 weeks (p = 0.022) and after 8 weeks of treatment, although the difference at the end of treatment was not significant ( p = 0.08).
  • Psychological fatigue, measured according to FIS-40, also showed a significant improvement (p <0.05) in the treatment group at the 4-week visit.
  • CoQ10 + NADH showed significant improvements in the quality of life relateted to physical performance during follow-up visits, measured according to SF-36 (p <0.05).
  • CoQ10 + NADH induced a significant improvement in body pain after 4 weeks of treatment, measured according to SF-36 (p <0.05).
  • CoQ10 + NADH significantly improved sleep quality at the end of treatment (p <0.05) as measured by PSQI.
  • CoQ10 + NADH have not presented relevant adverse effects throughout the study.


  • CoQ10 and NADH are bioenergetic cofactors with the potential to stimulate mitochondrial function, improving the mitochondrial dysfunction.
  • The combination of CoQ10 + NADH has a positive effect on cognitive fatigue, global fatigue and sleep quality.
  • The combination of CoQ10 + NADH has been shown to be effective in improving body pain and quality of life in patients with Chronic Fatigue Syndrome.
  • CoQ10 + NADH is a safe and well tolerated supplementation.

If you want to read the specific study, you can download it by clicking here.

Need help? From 08:30h - 18:00h here